Dear Candidate,
The British Pharmacopoeia (BP), one of the oldest pharmacopoeias, has been continually published since 1864. As a Commissioner, you will help maintain the BP's global leadership in medicine standards, drive scientific innovation, and ensure the consistent quality of safe and effective UK medicines.
You will join a diverse group of 17 commissioners from various fields who meet three times a year to discuss technical matters, set strategic goals, and oversee scientific and logistical policies.
While no Commissioner is expected to be an expert in all topics, all must contribute to strategy and policy discussions. The Commission is independent, requiring commissioners to be pragmatic, strive for high standards, and engage in open, constructive critique to form practical recommendations for national and global excellence.
Dr Anna-Maria Brady
BPC Chair
The British Pharmacopoeia Commission (BPC) was established under Section 4 of the Medicines Act 1968 (superseded by the Human Medicines Regulations 2012). It is responsible for preparing new editions of the British Pharmacopoeia (BP) and British Pharmacopoeia (Veterinary) and for keeping them up to date.
Used in over 100 countries, the specifications for medicines published in the BP play a vital role in ensuring medicines quality in the UK and across the world. The BPC also provides advice to the United Kingdom delegation to the European Pharmacopoeia Commission, of which the United Kingdom is a member. It is also responsible for selecting and devising British Approved Names.
The
British Pharmacopoeia Commission was established in 1970 under Section 4 of the
Medicines Act 1968 (superseded by the Human Medicines Regulations 2012). It is
an Advisory Non-Departmental Public Body, sponsored by the Department of Health
and Social Care. As such, it has no staff but is supported by a Secretariat
from the Medicines and Healthcare products Regulatory Agency (MHRA). It has
strong links with the wider MHRA, in particular with the Scientific Research
& Innovation Group (which encompasses staff from the National Institute of
Biological Standards and Control site at South Mimms), with the pharmaceutical
industry, the Cell and Gene Therapy Catapult and academia.
The
key role of the BPC is the preparation of the annual editions of the British
Pharmacopoeia (BP), which is widely recognised as one of the leading global
pharmacopoeias. The publicly available and legally enforceable pharmacopeial
standards are designed to complement and assist the licensing and inspection
processes and are part of the system for safeguarding purchasers and users of
medicinal products in the UK.
The
BPC has responded to the changing pharmaceutical environment, to changes in
priorities for the European Pharmacopoeia Commission and to the changes taking
place within the MHRA to ensure that the agency is fit for the future. This
includes supporting innovation and ensuring the safe production and supply of
medicines. The MHRA has recently undergone a major transformation and the BPC
has an important role to play in the new agency.
Current
strategic priorities for the BPC include the development of appropriate
standards for biological medicines, particularly in the area of Advanced
Therapy Medicinal Products, and continuing the work looking at the potential
application of Analytical Quality by Design principles to the development of
national monographs. Combined with an ongoing review of the work programme, and
forthcoming improvements to the BP website, these key areas of work will ensure
that the BP continues to provide appropriate quality standards that will
provide the most benefit to patients and will improve the experience for users
of the BP. The BPC also plays a significant role in the work of the European
Pharmacopoeia, contributing to the development of policies and monographs for
that pharmacopoeia, and works closely with other national and international
pharmacopoeias.
Members
of the BPC also serve on the Expert Advisory Groups and Panels of Experts
responsible for developing national monographs, thereby ensuring that the
strategic priorities of the BP Commission are implemented within these groups.
All members are required to comply with the MHRA Code of Practice on Identifying, Declaring and
Managing Interests.
An
annual report, highlighting the work of the BPC, is published each year. The
most recent report is for 2023 (Annual Report 2023) .
For further
information, see the BP website (BP Commission)
The BPC usually holds three meetings per year. Members will also be required to attend meetings of the Expert Advisory Groups (EAG) or Panels of Experts to which they are appointed. This will be for a maximum of 2 meetings per EAG each year.
Meetings are currently scheduled for:
3 November 2025
2 March 2026
29 June 2026
The March meeting is usually held in person at the MHRA offices in London with other meeting being held remotely.
This post is regulated by the Commissioner for Public Appointments. For more information, please refer to the
Commissioner’s website